IRIS
TALAMONTI, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.413
AS - Asia 3.244
EU - Europa 2.060
SA - Sud America 461
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 7
Totale 21.257
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.291
SG - Singapore 1.463
CN - Cina 613
RU - Federazione Russa 404
BR - Brasile 383
HK - Hong Kong 357
IT - Italia 346
IE - Irlanda 299
VN - Vietnam 256
DE - Germania 238
BD - Bangladesh 181
FR - Francia 171
GB - Regno Unito 129
UA - Ucraina 119
SE - Svezia 101
JP - Giappone 87
FI - Finlandia 82
CA - Canada 73
IN - India 65
KR - Corea 46
ID - Indonesia 32
PL - Polonia 32
NL - Olanda 30
AR - Argentina 29
ES - Italia 29
AT - Austria 22
MX - Messico 21
TR - Turchia 21
ZA - Sudafrica 17
IQ - Iraq 15
MY - Malesia 13
KG - Kirghizistan 12
CO - Colombia 11
EG - Egitto 11
EC - Ecuador 10
MA - Marocco 10
CL - Cile 9
PK - Pakistan 9
UZ - Uzbekistan 9
BE - Belgio 8
DZ - Algeria 8
KZ - Kazakistan 8
NP - Nepal 8
PH - Filippine 8
PY - Paraguay 8
AU - Australia 7
IL - Israele 7
RO - Romania 7
TW - Taiwan 7
CH - Svizzera 6
CZ - Repubblica Ceca 6
EU - Europa 6
GR - Grecia 6
VE - Venezuela 6
ET - Etiopia 5
JM - Giamaica 5
JO - Giordania 5
LT - Lituania 5
TH - Thailandia 5
KE - Kenya 4
LV - Lettonia 4
UY - Uruguay 4
AZ - Azerbaigian 3
GT - Guatemala 3
HN - Honduras 3
LB - Libano 3
MN - Mongolia 3
SA - Arabia Saudita 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GH - Ghana 2
HU - Ungheria 2
IR - Iran 2
PA - Panama 2
TN - Tunisia 2
VC - Saint Vincent e Grenadine 2
AD - Andorra 1
AL - Albania 1
AW - Aruba 1
BF - Burkina Faso 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CU - Cuba 1
GE - Georgia 1
GP - Guadalupe 1
KY - Cayman, isole 1
MD - Moldavia 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
Totale 21.252
Salva come PNG Salva come JPEG
Città #
Wilmington 3.385
Houston 3.230
Woodbridge 2.183
Fairfield 872
Singapore 782
Ashburn 712
Chandler 510
San Jose 405
Seattle 395
Hong Kong 354
Cambridge 307
Ann Arbor 301
Dublin 282
Beijing 235
Medford 211
Council Bluffs 192
Dallas 159
Santa Clara 144
New York 141
The Dalles 129
Los Angeles 110
Dearborn 102
Lawrence 101
Lauterbourg 86
Jacksonville 82
Tokyo 79
Hanoi 73
Munich 73
Ho Chi Minh City 71
Moscow 67
San Diego 64
Rome 61
Buffalo 59
Helsinki 41
São Paulo 36
London 33
Redondo Beach 30
Zhengzhou 30
Nuremberg 29
Redwood City 25
Shanghai 25
Chennai 24
Toronto 24
Milan 23
Boardman 20
Brooklyn 20
Chicago 19
Jakarta 19
Orem 19
Denver 18
Menlo Park 18
Seoul 18
Atlanta 16
Montreal 15
North Bergen 15
Washington 15
Falls Church 14
Guangzhou 14
Kraków 14
Lappeenranta 14
San Francisco 14
Warsaw 14
Esslingen am Neckar 13
Pune 13
Columbus 12
Norwalk 12
Stockholm 12
Ankara 11
Johannesburg 11
Manchester 11
Poplar 11
Da Nang 10
Frankfurt am Main 10
Mountain View 10
Phoenix 10
Perugia 9
Saint Petersburg 9
Belo Horizonte 8
Boston 8
Del Norte 8
Hefei 8
Mexico City 8
Nanjing 8
Ottawa 8
Porto Alegre 8
Salt Lake City 8
Vienna 8
Brussels 7
Curitiba 7
Detroit 7
Haiphong 7
Mülheim 7
Naples 7
Turin 7
Alexandria 6
Amsterdam 6
Charlotte 6
Chengdu 6
Dhaka 6
Nanchang 6
Totale 16.902
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 534
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. 485
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 473
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 458
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 439
Brodalumab for the treatment of psoriasis 439
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 438
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 437
Tildrakizumab for treating psoriasis 423
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 421
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 413
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 406
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 402
Tofacitinib for the treatment of psoriasis 400
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 398
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 394
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 370
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 370
A safety evaluation of guselkumab for the treatment of psoriasis 369
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 353
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 342
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 342
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 325
Photo-recall cutaneous reaction to gemcitabine 323
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 311
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 300
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 297
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 290
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 284
Pharmacotherapeutic management of psoriasis in adolescents and children 271
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 267
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 260
Skin immunity and its dysregulation in psoriasis 260
Successful treatment of psoriatic crumbly nails with ustekinumab 244
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 237
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 223
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 222
Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life 217
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 213
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 209
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab 198
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 198
Efalizumab 187
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 179
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 178
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers 175
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience 160
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 157
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis 156
Genetic markers predictive of clinical response to biological drugs in psoriasis. 145
Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study 142
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 140
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 140
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 133
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 132
Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension 131
Italian guidelines in diagnosis and treatment of alopecia areata 131
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 129
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 125
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 123
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 122
Clinical severity instruments 122
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis 121
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 120
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 118
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 112
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 111
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 108
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 107
Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study 107
Long-term efficacy of adalimumab in generalized pustular psoriasis 100
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 98
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 98
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 98
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 97
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry 96
Italian Guidelines in Pemphigus - adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV) 95
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 93
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 92
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 92
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes 92
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry 91
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 89
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 88
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes Abstracts of the 4th Congress of the Psoriasis International Network. July 4-6, 2013. Paris, France 86
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 86
Quality of life and psychological impact in patients with atopic dermatitis 86
Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics 85
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 85
Linear psoriasis following the typical distribution of the sciatic nerve 85
Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis 85
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 85
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 83
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 82
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 81
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 79
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 78
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 77
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 75
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 72
Totale 20.695
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.437
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.437
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.134 65 101 107 35 29 52 139 42 84 87 84 309
2022/20231.216 142 125 104 117 78 299 91 61 102 21 45 31
2023/2024524 41 14 22 13 65 121 68 64 4 8 27 77
2024/20252.387 121 453 268 238 33 231 152 99 221 209 187 175
2025/20264.593 305 184 582 324 376 157 629 476 512 436 301 311
2026/202722 22 0 0 0 0 0 0 0 0 0 0 0
Totale 21.921